Last updated on May 2019

A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3K-delta Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)


Brief description of study

The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

 

Clinical Study Identifier: TX203807

Find a site near you

Start Over

HOPITAL SAINT-LOUIS

Located in: PARIS, France
5.72miles
  Connect »

AVICENNE HOSPITAL

Located in: Bobigny, France
7.71miles
  Connect »

HOPITAL UNIVERSITAIRE PITIE SALPETRIERE

Located in: Paris, France
7.93miles
  Connect »